ReviewFrontiers in cardiovascular medicine2022
The factors influencing the efficiency of drug-coated balloons.
Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Comparison of Hybrid Strategy With Drug-Coated Balloons Versus Stent-Only Strategy for Coronary Bifurcation Lesions: A Systematic Review and Meta-Analysis.Cardiovascular therapeutics · 2026Pooled it
- Pooled it
- Comparison of Efficacy and Safety Between Drug-Coated Balloons Versus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions in Large Vessels: A Study-Level Meta-Analysis of Randomized Control Trials.Cardiovascular drugs and therapy · 2024Pooled it
- Impact of the drug-coated balloon-to-predilation balloon diameter ratio on restenosis risk in hemodialysis access: a study of nonlinear association.Renal failure · 2026Article
- Arterial remodeling and plaque changes after balloon angioplasty for de novo coronary lesions using DCB.Cardiovascular intervention and therapeutics · 2026Article
- Physiologically Adaptive Soft Millirobot for Atraumatic Endovascular Therapy.Advanced functional materials · 2026Article
- Association of Thyroid Function With Restenosis and Long-Term Outcomes After Drug-Coated Balloon Angioplasty in Euthyroid Patients With Coronary Heart Disease.Reviews in cardiovascular medicine · 2026Article
- Drug-Coated Balloons in Coronary Bifurcation Disease: A State-of-the-Art Review.Journal of personalized medicine · 2026Review
- Predictors of target lesion revascularization after paclitaxel-coated balloon angioplasty forFrontiers in cardiovascular medicine · 2026Article
- Efficacy of Sirolimus Versus Paclitaxel-Coated Balloons for Coronary Revascularization: An Updated Meta-Analysis with GRADE Assessment.Journal of the Saudi Heart Association · 2026Review
- Towards the Integration of an Anti-Contractile Compound Within Drug-Coated Balloon Therapy.Cardiovascular engineering and technology · 2025Article
- Physiologically Adaptive Soft Millirobot for Atraumatic, Image-Guided Endovascular Therapy.Research square · 2025Article
- DynamX Bioadaptor as an Emerging and Promising Innovation in Interventional Cardiology.Life (Basel, Switzerland) · 2025Review
- Comparison of High-Dose versus Low-Dose Paclitaxel Drug-Coated Balloons for Native Femoropopliteal Artery Disease: An Analysis of the K-VIS ELLA Registry.Yonsei medical journal · 2025Article
- Advances in drug-coated balloons for the treatment of coronary artery de novo large-vessel lesions.The Journal of international medical research · 2025Review
- Drug Loss at Arterial Bends Can Dominate Off-Target Drug Delivery by Paclitaxel-Coated Balloons.Pharmaceutics · 2025Article
- Culprit-Lesion Drug-Coated-Balloon Percutaneous Coronary Intervention in Patients Presenting with ST-Elevation Myocardial Infarction (STEMI).Journal of clinical medicine · 2025Article
- Drug coated balloons in percutaneous coronary intervention: how can computational modelling help inform evolving clinical practice?Frontiers in medical technology · 2025Review
- A Meta-Analysis of 3-Year Outcomes of Drug-Coated Balloons Versus Drug-Eluting Stents for Small-Vessel Coronary Artery Disease.JACC. Advances · 2024Article
- Benefits and Challenges of Drug-Coated Balloons in Peripheral Artery Disease: From Molecular Mechanisms to Clinical Practice.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The drug-coated balloon (DCB) is an emerging percutaneous coronary intervention (PCI) device that delivers drugs to diseased vessels to decrease the rate of vascular stenosis. Recent clinical studies have demonstrated that DCBs tend to have both good safety and efficacy profiles, leading to extended application indications in the clinic, including in-stent restenosis (ISR) for metal stents such as drug-eluting stents (DESs), small vascular disease, bifurcation disease, large vascular disease, acute coronary syndrome (ACS), and high bleeding risk. However, some previous clinical data have suggested that DCBs performed less effectively than DESs. No studies or reviews have systematically discussed the improvement strategies for better DCB performance until now. Drug loss during the process of delivery to the target lesion and inefficient delivery of the coating drug to the diseased vascular wall are two key mechanisms that weaken the efficiency of DCBs. This review is the first to summarize the key influencing factors of DCB efficiency in terms of balloon structure and principles, and then it analyzes how these factors cause outcomes in practice based on current clinical trial studies of DCBs in the treatment of different types of lesions. We also provide some recommendations for improving DCBs to contribute to better DCB performance by improving the design of DCBs and combining other factors in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.